Endometrial Cancer Market Size, Share, Growth Analysis, By Cancer Type(Type I and type II endometrial cancer), By Treatment(Surgery, radiation therapy, chemotherapy, hormone therapy), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35H2202 | Region: Global | Published Date: February, 2024
Pages: 157 |Tables: 63 |Figures: 75

Endometrial Cancer Market Insights

Endometrial Cancer Market size was valued at USD 28.3 billion in 2022 and is poised to grow from USD 28.69 billion in 2023 to USD 43.53 billion by 2031, at a CAGR of 4.9% during the forecast period (2024-2031).

The global endometrial cancer market is witnessing significant growth and advancements in the diagnosis, treatment, and management of the disease. Rising incidence rates of endometrial cancer, increasing awareness among individuals, and improved healthcare infrastructure are driving market growth.

Technological innovations in diagnostic tools, such as molecular profiling and genetic testing, have enabled accurate and personalized treatment approaches. Additionally, the development of targeted therapies, immunotherapies, and combination treatment modalities are further propelling market expansion.

Advancements in diagnostic techniques, such as genomic profiling and liquid biopsies, are enabling early detection and personalized treatment approaches. Additionally, targeted therapies and immunotherapies are gaining prominence, offering improved efficacy and reduced side effects compared to traditional treatments.

However, challenges such as high treatment costs, limited accessibility to advanced healthcare facilities, and the need for effective early detection methods remain important considerations in addressing the global burden of endometrial cancer.

US Endometrial Cancer Market is poised to grow at a sustainable CAGR for the next forecast year.

Market Snapshot - 2024-2031

Global Market Size

USD 28.3 billion

Largest Segment

surgery

Fastest Growth

surgery

Growth Rate

4.9% CAGR

Global Endometrial Cancer Market by region
Country Share for North America (%)

To get more reports on the above market click here to Buy The Report

Endometrial Cancer Market Segmental Analysis

The global endometrial cancer market can be analyzed based on cancer type, treatment, and region. In terms of cancer type, the market can be divided into type I and type II endometrial cancer. Based on treatment, the market can be segmented into surgery, radiation therapy, chemotherapy, hormone therapy, and targeted therapy. Geographically, the market can be categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Endometrial Cancer Market Analysis By Cancer Type

Type I endometrial cancer, specifically endometrioid adenocarcinoma, represents the largest sector in the global endometrial cancer market. It accounts for the majority of diagnosed cases of endometrial cancer. Type I endometrial cancer is typically diagnosed at an early stage due to its characteristic symptoms, such as abnormal uterine bleeding, which prompts women to seek medical attention. Moreover, advancements in diagnostic techniques, such as endometrial biopsy and imaging modalities, have facilitated early detection and improved the overall survival rates for patients with type I endometrial cancer.

The fastest-growing sector in the global endometrial cancer market is type II endometrial cancer. Although less common, type II endometrial cancer is associated with a higher risk of recurrence and metastasis, necessitating aggressive treatment approaches. Research and clinical trials focusing on targeted therapies and novel treatment options for type II endometrial cancer are actively ongoing. The development of personalized medicine and immunotherapies has shown promising results in improving outcomes for patients with type II endometrial cancer. The growing understanding of the molecular and genetic characteristics of type II endometrial cancer is paving the way for more effective and tailored treatments, driving the growth of this sector in the global market.

Endometrial Cancer Market Analysis By Treatment

The largest sector in the global endometrial cancer market is likely to be surgery. Surgical intervention, particularly hysterectomy, is the primary treatment for endometrial cancer. It is often the first line of treatment for localized tumors that have not spread beyond the uterus. Surgery offers the potential for complete removal of the cancerous tissue and provides valuable information about the stage and grade of the cancer.

The fastest growing sector in the global endometrial cancer market is expected to be targeted therapy. Targeted therapies have shown promise in various types of cancers, including endometrial cancer. These therapies specifically target certain molecules or pathways involved in cancer growth, which can lead to more effective and less toxic treatments. Advancements in understanding the molecular and genetic characteristics of endometrial cancer have led to the development of targeted therapies that can specifically attack cancer cells while sparing healthy tissues. These therapies have the potential to improve outcomes and offer new treatment options for patients with advanced or recurrent endometrial cancer.

Global Endometrial Cancer Market by treatment type

To get detailed analysis on other segments, Request For Free Sample Report

Endometrial Cancer Market Regional Insights

North America holds a significant market share due to advanced healthcare infrastructure, rising incidence rates, and increasing adoption of innovative treatment options.

Europe follows suit with a focus on clinical research, robust regulatory frameworks, and growing awareness among healthcare professionals and patients.

The Asia-Pacific region witnesses a rising burden of endometrial cancer due to lifestyle changes, aging population, and limited access to healthcare.

Emerging economies in Latin America and the Middle East show growing market potential as healthcare infrastructure improves and awareness campaigns gain traction.

Global Endometrial Cancer Market by geography
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Endometrial Cancer Market Dynamics

Endometrial Cancer Market Drivers

Increasing Investment on Developing Healthcare Infrastructure

  • One driver in the global endometrial cancer market is the increasing prevalence of endometrial cancer worldwide. Endometrial cancer is one of the most common gynecological cancers, and its incidence has been steadily rising over the years. The growing prevalence of risk factors such as obesity, hormonal imbalances, and diabetes contributes to the higher incidence of endometrial cancer. This increased prevalence drives the demand for effective diagnostic and therapeutic solutions, leading to market growth.
  • Advancements in medical technology and improved screening methods also fuel the market, as they enable early detection and treatment of endometrial cancer, improving patient outcomes.

Endometrial Cancer Market Restraints

Lack of Accessibility and High Cost

  • One restraint in the global endometrial cancer market is the high cost of treatment and limited healthcare access, especially in developing regions. The cost of endometrial cancer treatment, including surgeries, chemotherapy, and radiation therapy, can be substantial, placing a financial burden on patients. This restricts access to optimal care and therapies for many individuals, particularly those without adequate health insurance or resources.
  • In some regions, there may be a lack of healthcare infrastructure, including diagnostic facilities and specialized healthcare professionals, further limiting timely and effective management of endometrial cancer. Addressing these challenges and improving affordability and accessibility to quality care are crucial for overcoming this restraint and improving patient outcomes globally.

Request Free Customization of this report to help us to meet your business objectives.

Endometrial Cancer Market Competitive Landscape

The global endometrial cancer market features a competitive landscape with several prominent players vying for market share. These companies are focused on developing targeted therapies, immunotherapies, and combination therapies to improve patient outcomes. Additionally, strategic collaborations, mergers, and acquisitions are common strategies employed by these players to strengthen their market position. With a strong emphasis on technological advancements and personalized medicine, the competitive landscape of the global endometrial cancer market remains dynamic and driven by constant innovation.

Endometrial Cancer Market Top Player’s Company Profiles

  • Roche Holdings AG (Switzerland)
  • Merck & Co., Inc. (United States)
  • AstraZeneca PLC (United Kingdom)
  • Pfizer Inc. (United States)
  • Novartis AG (Switzerland)
  • Johnson & Johnson (United States)
  • Bristol-Myers Squibb Company (United States)
  • Eli Lilly and Company (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • AbbVie Inc. (United States)
  • Celgene Corporation (United States)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Sanofi S.A. (France)
  • Amgen Inc. (United States)
  • Bayer AG (Germany)
  • Gilead Sciences, Inc. (United States)
  • Biogen Inc. (United States)
  • Eisai Co., Ltd. (Japan)
  • Incyte Corporation (United States)
  • Astellas Pharma Inc. (Japan)

Endometrial Cancer Market Recent Developments

• In October 2022, Sysmex Corporation announced the approval of an application for a partial change to the manufacturing and marketing approval in Japan of its gene amplification reagent LYNOAMP CK19, expanding its amplification to cervical cancer and endometrial cancer. This reagent is marketed as a lymph node metastasis test reagent for breast cancer, colorectal cancer, gastric cancer, and non-small cell lung cancer.

Endometrial Cancer Key Market Trends

  • The market is witnessing collaborations and partnerships between pharmaceutical companies and research institutions to accelerate drug development and clinical trials. Overall, these trends are shaping the endometrial cancer market towards improved diagnostics, novel therapies, and better patient outcomes.

Endometrial Cancer Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Product types team that Collects, Collates, Co-relates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.

According to our analysis, the global endometrial cancer market holds promising prospects for the future. Advances in technology and medical research have paved the way for the development of innovative treatment modalities, such as targeted therapies and immunotherapies, that show potential in improving patient outcomes. Additionally, precision medicine approaches, including molecular profiling and genetic testing, offer personalized treatment options for patients based on their unique genetic makeup and tumor characteristics. Furthermore, ongoing research and clinical trials focusing on novel biomarkers, early detection methods, and minimally invasive surgical techniques hold promise for early diagnosis and improved survival rates.

Report Metric Details
Market size value in 2022 USD 28.3 billion
Market size value in 2031 USD 43.53 billion
Growth Rate 4.9%
Base year 2023
Forecast period 2024-2031
Forecast Unit (Value) USD Billion
Segments covered
  • Cancer Type
    • Type I and type II endometrial cancer
  • Treatment
    • Surgery, radiation therapy, chemotherapy, hormone therapy, and targeted therapy
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Roche Holdings AG (Switzerland)
  • Merck & Co., Inc. (United States)
  • AstraZeneca PLC (United Kingdom)
  • Pfizer Inc. (United States)
  • Novartis AG (Switzerland)
  • Johnson & Johnson (United States)
  • Bristol-Myers Squibb Company (United States)
  • Eli Lilly and Company (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • AbbVie Inc. (United States)
  • Celgene Corporation (United States)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Sanofi S.A. (France)
  • Amgen Inc. (United States)
  • Bayer AG (Germany)
  • Gilead Sciences, Inc. (United States)
  • Biogen Inc. (United States)
  • Eisai Co., Ltd. (Japan)
  • Incyte Corporation (United States)
  • Astellas Pharma Inc. (Japan)
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Endometrial Cancer Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Endometrial Cancer Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Endometrial Cancer Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Endometrial Cancer Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Endometrial Cancer Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Endometrial Cancer Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Endometrial Cancer Market size was valued at USD 28.3 billion in 2022 and is poised to grow from USD 28.69 billion in 2023 to USD 43.53 billion by 2031, at a CAGR of 4.9% during the forecast period (2024-2031).

The global endometrial cancer market features a competitive landscape with several prominent players vying for market share. These companies are focused on developing targeted therapies, immunotherapies, and combination therapies to improve patient outcomes. Additionally, strategic collaborations, mergers, and acquisitions are common strategies employed by these players to strengthen their market position. With a strong emphasis on technological advancements and personalized medicine, the competitive landscape of the global endometrial cancer market remains dynamic and driven by constant innovation. 'Roche Holdings AG (Switzerland)', 'Merck & Co., Inc. (United States)', 'AstraZeneca PLC (United Kingdom)', 'Pfizer Inc. (United States)', 'Novartis AG (Switzerland)', 'Johnson & Johnson (United States)', 'Bristol-Myers Squibb Company (United States)', 'Eli Lilly and Company (United States)', 'GlaxoSmithKline plc (United Kingdom)', 'AbbVie Inc. (United States)', 'Celgene Corporation (United States)', 'Takeda Pharmaceutical Company Limited (Japan)', 'Sanofi S.A. (France)', 'Amgen Inc. (United States)', 'Bayer AG (Germany)', 'Gilead Sciences, Inc. (United States)', 'Biogen Inc. (United States)', 'Eisai Co., Ltd. (Japan)', 'Incyte Corporation (United States)', 'Astellas Pharma Inc. (Japan)'

One driver in the global endometrial cancer market is the increasing prevalence of endometrial cancer worldwide. Endometrial cancer is one of the most common gynecological cancers, and its incidence has been steadily rising over the years. The growing prevalence of risk factors such as obesity, hormonal imbalances, and diabetes contributes to the higher incidence of endometrial cancer. This increased prevalence drives the demand for effective diagnostic and therapeutic solutions, leading to market growth.

The market is witnessing collaborations and partnerships between pharmaceutical companies and research institutions to accelerate drug development and clinical trials. Overall, these trends are shaping the endometrial cancer market towards improved diagnostics, novel therapies, and better patient outcomes.

North America holds a significant market share due to advanced healthcare infrastructure, rising incidence rates, and increasing adoption of innovative treatment options.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Report ID: SQMIG35H2202

$5,300
BUY NOW GET FREE SAMPLE